• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CareMax, Inc. Reports Third Quarter 2022 Results; Raises Full Year Revenue Outlook

    11/9/22 6:55:00 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care
    Get the next $CMAX alert in real time by email
    • Third Quarter 2022 Medicare Advantage Membership of 39,500, up 49% year-over-year
    • Third Quarter 2022 GAAP Total Revenue of $157.7 million, up 51% year-over-year
    • Expanded Presence with De Novo Openings in Brooklyn, New York; Queens, New York; and Plantation, Florida Since Quarter End
    • Raising Full Year 2022 Revenue Guidance; Excludes Expected Impact from Steward Acquisition

    CareMax, Inc. (NASDAQ:CMAX, CMAXW))) ("CareMax" or the "Company"), a leading technology-enabled provider of value-based care to seniors, today announced financial results for the third quarter ended September 30, 2022.

    "Our solid third quarter results are a testament to our focus on executing our strategy, operational excellence and the hard work of our team," said Carlos de Solo, Chief Executive Officer. "Once again, member growth exceeded our expectations, as patients continue to demonstrate and validate the extent to which they value our whole person health model. As a result of this continued growth, we are pleased to increase our full-year revenue outlook."

    Mr. de Solo continued, "Last week, CareMax's stockholders approved our issuance of stock as partial consideration for our transformative acquisition of Steward Health Care System's Medicare value-based care business. The transaction, which we anticipate will close promptly, will represent a major milestone in our efforts to redefine healthcare for seniors across the U.S. In the meantime, we are focused on our integration efforts, and look forward to realizing the benefits of this acquisition and leveraging our deep experience in managing at-risk populations to drive sustainable growth and enhanced value for our stakeholders."

    Third Quarter 2022 Results

    • Total revenue was $157.7 million, up 51% year-over-year.
    • Medical Expense Ratio was 75.2%, compared to 75.4% for the third quarter of 2021.1
    • Net loss was $22.1 million, or $(0.25) per diluted share, compared to net loss of $14.5 million, or $(0.18) per diluted share for the third quarter of 2021.
    • Adjusted EBITDA was $9.2 million, compared to $1.2 million for the third quarter of 2021.2
    • Platform Contribution was $20.7 million, compared to $11.0 million for the third quarter of 2021.2

    Recent Business Highlights

    • Stockholders approved the issuance of stock as partial consideration for the acquisition of the Medicare value-based care business of Steward Health Care System on November 2, 2022.
    • Expanded presence with de novo clinic openings in Brooklyn, New York; Queens, New York; and Plantation, Florida since quarter end, bringing total clinic count to 54.
    • Continued to invest in our talent to support our platform infrastructure with the addition of a Chief Accounting Officer and Chief Digital Officer.

    Financial Outlook for Full Year 2022; Excludes Expected Impact from Steward Acquisition2,3

    CareMax is raising the following full year 2022 financial guidance:

    • Total revenue of $600 million to $620 million, up 49% to 54% year-over-year compared to $403 million for full year 2021, from prior guidance of $580 million to $600 million.

    CareMax is reaffirming the following full year 2022 financial guidance:

    • Year-end Medicare Advantage membership of greater than 40,000, up over 19% year-over-year.
    • Adjusted EBITDA in the range of $30 million to $40 million, up 125% to 200% year-over-year, compared to $13.3 million for the prior year. For 2022, Adjusted EBITDA also excludes losses from de novo centers.
    • The Company continues to expect to open 15 de novo centers in 2022, inclusive of 9 openings to-date.

    1Medical Expense Ratio equals external provider costs divided by Medicare and Medicaid risk-based revenues.

    2Adjusted EBITDA and Platform Contribution are non-GAAP financial metrics. A reconciliation of non-GAAP metrics to the most directly comparable GAAP financial measures is included in this earnings release.

    3Pro Forma year-over-year comparisons to 2021 reflect the business combinations of IMC Medical Group Holdings and Care Holdings as if they had occurred on January 1, 2021. A reconciliation of the pro forma financial information to GAAP financial statements is included in this earnings release.

    Conference Call Details

    Management will host a conference call at 8:30 am ET today to discuss the results. The conference call can be accessed by dialing (888) 330-2508 for U.S. participants, or (240) 789-2735 for international participants, and referencing conference ID 7874605. A live audio webcast as well as related presentation materials will also be available on the "Events & Presentations" section of CareMax's investor relations website at ir.caremax.com. Following the live call, a replay will be available on the Company's website.

    About CareMax

    CareMax is a technology-enabled care platform providing value-based care and chronic disease management to seniors. CareMax operates centers that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States. Learn more at www.caremax.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth, strategy and financial performance, the closing of the Steward transaction and the benefits thereof, and the filing of the Company's periodic reports. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," "pro-forma," "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements reflect the Company's expectations, plans or forecasts of future events and views as of the date of this press release. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

    Important risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, whether the Company's pending acquisition of Steward Value-Based Care will close and the risks associated therewith, the impact of COVID-19 or any variant thereof on the Company's business and results of operation; the availability of sites for de novo centers and the costs of opening such de novo centers; changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to the Company's services; the Company's ability to continue its growth, including in new markets; changes in laws and regulations applicable to the Company's business, in particular with respect to Medicare Advantage and Medicaid; the Company's ability to maintain its relationships with health plans and other key payers; any delay, modification or cancellation of government contracts; the Company's future capital requirements and sources and uses of cash, including funds to satisfy its liquidity needs and the Company's ability to comply with the covenants under its credit agreement; the Company's ability to recruit and retain qualified team members and independent physicians; and risks related to future acquisitions. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's reports filed with the SEC. All information provided in this press release is as of the date hereof, and the Company undertakes no duty to update or revise this information unless required by law, and forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this press release.

    Use of Non-GAAP Financial Information

    Certain financial information and data contained in this press release is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any periodic filing, information or proxy statement, or prospectus or registration statement to be filed by the Company with the SEC. Some of the financial information and data contained in this press release, such as Adjusted EBITDA and Platform Contribution and margin thereof have not been prepared in accordance with United States generally accepted accounting principles ("GAAP"). These non-GAAP measures of financial results are not GAAP measures of our financial results or liquidity and should not be considered as an alternative to net income (loss) as a measure of financial results, cash flows from operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company's management uses these non-GAAP measures for trend analyses and for budgeting and planning purposes.

    The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing the Company's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company's financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. For this reason, these non-GAAP measures may not be comparable to other Companies' similarly labeled non-GAAP financial measures. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. You should review the Company's audited financial statements, which have been filed by the Company with the SEC.

    A reconciliation for Adjusted EBITDA and Platform Contribution to the most directly comparable GAAP financial measures is included below. A reconciliation of projected 2022 Adjusted EBITDA to the most directly comparable GAAP financial measure is not included in this press release because, without unreasonable efforts, the Company is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate this. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company's future GAAP results.

    Use of Pro Forma Financial Information and Pro Forma Non-GAAP Financial Information

    Certain of the information presented in the Non-GAAP Financial Summary and in the reconciliations to non-GAAP financial measures includes pro forma information derived from the unaudited pro forma statements of operations which are provided for informational purposes only and are not necessarily indicative of the operating results or financial position that would have occurred if the acquisitions of IMC and Care Holdings had occurred in the stated historical periods, nor are they indicative of the future results or financial position of the combined company. The unaudited pro forma statements of operations do not give effect to the potential impact, of any anticipated synergies, operating efficiencies or cost savings that may result from the acquisitions of IMC and Care Holdings, any integration costs or tax deductibility of transaction costs.

    Additionally, Adjusted EBITDA presented on a pro forma basis gives effect to the acquisitions of IMC and Care Holdings as if they had occurred in historical periods. Such non-GAAP financial measures do not necessarily reflect what the Company's Adjusted EBITDA would have been had the acquisitions occurred on the dates indicated.

    CAREMAX, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except share and per share data)

    (Unaudited)

     

     

    September 30,

    2022

     

     

    December 31,

    2021

     

    ASSETS

     

     

     

     

     

     

     

     

     

     

     

     

     

    Current Assets

     

     

     

     

     

     

    Cash

     

    $

    53,315

     

     

    $

    47,917

     

    Accounts receivable, net

     

     

    85,766

     

     

     

    41,998

     

    Inventory

     

     

    911

     

     

     

    550

     

    Warrants and prepaid expenses

     

     

    21,653

     

     

     

    17,040

     

    Risk settlements due from providers

     

     

    537

     

     

     

    539

     

    Total Current Assets

     

     

    162,183

     

     

     

    108,044

     

     

     

     

     

     

     

     

    Property and equipment, net

     

     

    18,125

     

     

     

    15,993

     

    Goodwill

     

     

    465,058

     

     

     

    464,566

     

    Intangible assets, net

     

     

    48,166

     

     

     

    59,811

     

    Deferred debt issuance costs

     

     

    2,644

     

     

     

    1,972

     

    Other assets

     

     

    11,258

     

     

     

    2,706

     

    Total Assets

    $

    707,433

     

     

    $

    653,092

     

     

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

     

     

     

     

     

     

     

    Current Liabilities

     

     

     

     

     

     

    Accounts payable

     

    $

    13,422

     

     

    $

    3,110

     

    Accrued expenses

     

     

    16,630

     

     

     

    8,690

     

    Risk settlements due to providers

     

     

    50

     

     

     

    196

     

    Current portion of long-term debt

     

     

    159

     

     

     

    6,275

     

    Other current liabilities

     

     

    3,485

     

     

     

    3,687

     

    Total Current Liabilities

     

     

    33,745

     

     

     

    21,959

     

     

     

     

     

     

     

     

    Derivative warrant liabilities

     

     

    11,851

     

     

     

    8,375

     

    Long-term debt

     

     

    184,253

     

     

     

    110,960

     

    Other liabilities

     

     

    8,379

     

     

     

    6,428

     

    Total Liabilities

     

     

    238,228

     

     

     

    147,722

     

    COMMITMENTS AND CONTINGENCIES (NOTE 13)

     

     

     

     

     

     

    STOCKHOLDERS' EQUITY

     

     

     

     

     

     

    Preferred stock (1,000,000 authorized and none outstanding as of September 30, 2022 and December 31, 2021)

     

     

    -

     

     

     

    -

     

    Class A common stock ($0.0001 par value; 250,000,000 shares authorized; 87,396,972 and 87,367,972 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively)

     

     

    9

     

     

     

    9

     

    Additional paid-in-capital

     

     

    517,393

     

     

     

    505,327

     

    Retained earnings (deficit)

     

     

    (48,197

    )

    33

     

    Total Stockholders' Equity

     

     

    469,205

     

     

     

    505,370

     

     

     

     

     

     

     

     

    Total Liabilities and Stockholders' Equity

     

    $

    707,433

     

     

    $

    653,092

     

    CAREMAX, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except share and per share data)

    (Unaudited)

     

     

    Three Months Ended September 30,

     

     

    Nine Months Ended September 30,

     

     

     

    2022

     

     

    2021

     

     

    2022

     

     

    2021

     

    Revenue

     

     

     

     

     

     

     

     

     

     

     

     

    Medicare risk-based revenue

     

    $

    122,267

     

     

    $

    76,428

     

     

    $

    373,677

     

     

    $

    142,005

     

    Medicaid risk-based revenue

     

     

    19,852

     

     

     

    20,884

     

     

     

    59,914

     

     

     

    26,333

     

    Other revenue

     

     

    15,551

     

     

     

    7,308

     

     

     

    33,278

     

     

     

    9,118

     

    Total revenue

     

     

    157,670

     

     

     

    104,620

     

     

     

    466,869

     

     

     

    177,456

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating expenses

     

     

     

     

     

     

     

     

     

     

     

     

    External provider costs

     

     

    106,900

     

     

     

    73,329

     

     

     

    320,104

     

     

     

    127,023

     

    Cost of care

     

     

    30,213

     

     

     

    21,602

     

     

     

    87,925

     

     

     

    34,822

     

    Sales and marketing

     

     

    2,355

     

     

     

    1,274

     

     

     

    7,955

     

     

     

    2,340

     

    Corporate, general and administrative

     

     

    21,687

     

     

     

    13,589

     

     

     

    58,728

     

     

     

    24,264

     

    Depreciation and amortization

     

     

    4,573

     

     

     

    5,176

     

     

     

    14,538

     

     

     

    7,127

     

    Acquisition related costs

     

     

    494

     

     

     

    879

     

     

     

    3,549

     

     

     

    1,028

     

    Total operating expenses

     

     

    166,222

     

     

     

    115,849

     

     

     

    492,799

     

     

     

    196,603

     

    Operating income (loss)

     

     

    (8,552

    )

     

     

    (11,229

    )

     

     

    (25,930

    )

     

     

    (19,147

    )

    Nonoperating income (expense)

     

     

     

     

     

     

     

     

     

     

     

     

    Interest expense

     

     

    (6,076

    )

     

     

    (1,291

    )

     

     

    (11,700

    )

     

     

    (2,587

    )

    Change in fair value of derivative warrant liabilities

     

     

    (7,331

    )

     

     

    10,227

     

     

     

    (3,476

    )

     

     

    12,022

     

    Gain (loss) on remeasurement of contingent earnout liabilities

     

     

    -

     

     

     

    (11,625

    )

     

     

    -

     

     

     

    5,794

     

    Gain (loss) on extinguishment of debt, net

     

     

    -

     

     

     

    279

     

     

     

    (6,172

    )

     

     

    1,637

     

    Other income (expense), net

     

     

    87

     

     

     

    (840

    )

     

     

    (420

    )

     

     

    (840

    )

     

     

     

    (13,320

    )

     

     

    (3,250

    )

     

     

    (21,768

    )

     

     

    16,026

     

    Income (loss) before income tax

     

     

    (21,872

    )

     

     

    (14,479

    )

     

     

    (47,698

    )

     

     

    (3,120

    )

    Income tax benefit (expense)

     

     

    (181

    )

     

     

    -

     

     

     

    (532

    )

     

     

    -

     

    Net income (loss)

     

    $

    (22,053

    )

     

    $

    (14,479

    )

     

    $

    (48,230

    )

     

    $

    (3,120

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted-average basic shares outstanding

     

     

    87,408,605

     

     

     

    82,552,520

     

     

     

    87,415,801

     

     

     

    40,847,294

     

    Weighted-average diluted shares outstanding

     

     

    87,408,605

     

     

     

    82,552,520

     

     

     

    87,415,801

     

     

     

    40,847,294

     

    Net income (loss) per share

     

     

     

     

     

     

     

     

     

     

     

     

    Basic

     

    $

    (0.25

    )

     

    $

    (0.18

    )

     

    $

    (0.55

    )

     

    $

    (0.08

    )

    Diluted

     

    $

    (0.25

    )

     

    $

    (0.18

    )

     

    $

    (0.55

    )

     

    $

    (0.08

    )

    CAREMAX, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

    (Unaudited)

     

     

    Nine Months Ended September 30,

     

     

     

    2022

     

     

    2021

     

    CASH FLOWS FROM OPERATING ACTIVITIES

     

     

     

     

     

     

    Net income (loss)

     

    $

    (48,230

    )

     

    $

    (3,120

    )

    Adjustments to reconcile net income (loss) to net cash

     

     

     

     

     

     

    Depreciation and amortization expense

     

     

    14,538

     

     

     

    7,145

     

    Amortization of debt issuance costs and discount

     

     

    1,093

     

     

     

    522

     

    Stock-based compensation expense

     

     

    7,486

     

     

     

    966

     

    Change in fair value of derivative warrant liabilities

     

     

    3,476

     

     

     

    (12,022

    )

    Loss (gain) on remeasurement of contingent earnout liabilities

     

     

    -

     

     

     

    (5,794

    )

    Loss (gain) on extinguishment of debt

     

     

    6,172

     

     

     

    (1,637

    )

    Payment-in-kind interest expense

     

     

    3,038

     

     

     

    -

     

    Other non-cash, net

     

     

    (242

    )

     

     

    -

     

    Changes in operating assets and liabilities:

     

     

     

     

     

     

    Accounts receivable, net

     

     

    (43,109

    )

     

     

    4,296

     

    Inventory

     

     

    (361

    )

     

     

    67

     

    Warrants and prepaid expenses

     

     

    292

     

     

     

    (1,371

    )

    Risk settlements due to (from) providers

     

     

    (144

    )

     

     

    (384

    )

    Due to (from) related parties

     

     

    -

     

     

     

    235

     

    Other assets

     

     

    (1,037

    )

     

     

    (312

    )

    Accounts payable

     

     

    9,291

     

     

     

    1,583

     

    Accrued expenses

     

     

    6,705

     

     

     

    (3

    )

    Other liabilities

     

     

    1,222

     

     

     

    1,029

     

    Net cash provided by (used in) operating activities

     

     

    (39,811

    )

     

     

    (8,801

    )

     

     

     

     

     

     

     

    CASH FLOWS FROM INVESTING ACTIVITIES

     

     

     

     

     

     

    Purchase of property and equipment

     

     

    (4,862

    )

     

     

    (2,967

    )

    Return of cash held in escrow

     

     

    785

     

     

     

    -

     

    Acquisition of businesses, net of cash acquired

     

     

    (892

    )

     

     

    (298,344

    )

    Net cash provided by (used in) investing activities

     

     

    (4,969

    )

     

     

    (301,311

    )

     

     

     

     

     

     

     

    CASH FLOWS FROM FINANCING ACTIVITIES

     

     

     

     

     

     

    Proceeds from issuance of Class A common stock

     

     

    -

     

     

     

    415,000

     

    Issuance costs of Class A common stock

     

     

    -

     

     

     

    (12,471

    )

    Recapitalization transaction

     

     

    -

     

     

     

    (108,386

    )

    Proceeds from borrowings

     

     

    184,000

     

     

     

    125,000

     

    Principal payments on long-term debt

     

     

    (121,926

    )

     

     

    (26,143

    )

    Payments of debt issuance costs

     

     

    (6,456

    )

     

     

    (6,883

    )

    Debt extinguishment costs

     

     

    -

     

     

     

    (487

    )

    Collateral for letters of credit

     

     

    (5,439

    )

     

     

    -

     

    Net cash provided by (used in) financing activities

     

     

    50,179

     

     

     

    385,630

     

     

     

     

     

     

     

     

    NET INCREASE IN CASH

     

     

    5,399

     

     

     

    75,518

     

    Cash - beginning of period

     

     

    47,917

     

     

     

    4,934

     

    CASH - END OF PERIOD

     

    $

    53,315

     

     

    $

    80,451

     

    Non-GAAP Financial Summary*

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    $ in thousands

    Sep 30, 2020

     

    Dec 31, 2020

     

    Mar 31, 2021

     

    Jun 30, 2021

     

    Sep 30, 2021

     

    Dec 31, 2021

     

    Mar 31, 2022

     

    Jun 30, 2022

     

    Sep 30, 2022

     

    Medicare risk-based revenue

    $

    63,188

     

    $

    65,210

     

    $

    65,394

     

    $

    66,618

     

    $

    76,428

     

    $

    91,277

     

    $

    107,747

     

    $

    143,664

     

    $

    122,267

     

    Medicaid risk-based revenue

     

    20,565

     

     

    19,062

     

     

    18,897

     

     

    20,454

     

     

    20,884

     

     

    20,160

     

     

    20,165

     

     

    19,896

     

     

    19,852

     

    Other revenue

     

    3,351

     

     

    3,801

     

     

    4,127

     

     

    4,839

     

     

    7,308

     

     

    6,869

     

     

    9,008

     

     

    8,719

     

     

    15,551

     

    Total revenue

     

    87,104

     

     

    88,073

     

     

    88,418

     

     

    91,911

     

     

    104,620

     

     

    118,306

     

     

    136,920

     

     

    172,279

     

     

    157,670

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    External provider costs

     

    60,158

     

     

    57,775

     

     

    60,278

     

     

    70,466

     

     

    73,329

     

     

    79,724

     

     

    92,856

     

     

    120,348

     

     

    106,900

     

    Cost of care

     

    11,417

     

     

    12,446

     

     

    13,427

     

     

    13,246

     

     

    20,315

     

     

    22,538

     

     

    26,791

     

     

    30,226

     

     

    30,084

     

    Platform contribution

     

    15,529

     

     

    17,852

     

     

    14,712

     

     

    8,199

     

     

    10,976

     

     

    16,044

     

     

    17,274

     

     

    21,705

     

     

    20,686

     

    Platform contribution margin (%)

     

    17.8

    %

     

    20.3

    %

     

    16.6

    %

     

    8.9

    %

     

    10.5

    %

     

    13.6

    %

     

    12.6

    %

     

    12.6

    %

     

    13.1

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Sales and marketing

    $

    1,290

     

    $

    1,431

     

    $

    391

     

    $

    1,688

     

    $

    1,274

     

    $

    2,615

     

    $

    3,301

     

    $

    2,299

     

    $

    2,355

     

    Corporate, general and administrative

     

    6,069

     

     

    6,519

     

     

    7,197

     

     

    6,347

     

     

    8,668

     

     

    9,662

     

     

    9,230

     

     

    11,024

     

     

    10,640

     

    Adjusted operating expenses

     

    7,359

     

     

    7,951

     

     

    7,588

     

     

    8,036

     

     

    9,942

     

     

    12,276

     

     

    12,531

     

     

    13,324

     

     

    12,996

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    De novo losses**

     

    68

     

     

    484

     

     

    184

     

     

    364

     

     

    195

     

     

    489

     

     

    1,119

     

     

    993

     

     

    1,533

     

    Adjusted EBITDA

    $

    8,237

     

    $

    10,385

     

    $

    7,308

     

    $

    527

     

    $

    1,229

     

    $

    4,257

     

    $

    5,862

     

    $

    9,374

     

    $

    9,224

     

    * Figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred in historical periods. Figures may not sum due to rounding.

     

    ** Includes operating losses incurred by de novo centers up to 18 months after opening.

     

    Non-GAAP Operating Metrics*

    Sep 30, 2020

     

    Dec 31, 2020

     

    Mar 31, 2021

     

    Jun 30, 2021

     

    Sep 30, 2021

     

    Dec 31, 2021

     

    Mar 31, 2022

     

    Jun 30, 2022

     

    Sep 30, 2022

     

    Centers

     

    22

     

     

    24

     

     

    24

     

     

    34

     

     

    40

     

     

    45

     

     

    48

     

     

    48

     

     

    51

     

    Markets

     

    1

     

     

    1

     

     

    1

     

     

    2

     

     

    3

     

     

    4

     

     

    6

     

     

    6

     

     

    7

     

    Patients (MCREM)**

     

    29,000

     

     

    28,400

     

     

    29,200

     

     

    35,300

     

     

    40,400

     

     

    50,100

     

     

    50,600

     

     

    54,000

     

     

    57,400

     

    At-Risk

     

    85.6

    %

     

    87.7

    %

     

    87.0

    %

     

    84.1

    %

     

    87.2

    %

     

    79.3

    %

     

    79.8

    %

     

    81.0

    %

     

    78.2

    %

    Platform Contribution ($, Millions)***

    $

    15.5

     

    $

    17.9

     

    $

    14.7

     

    $

    8.2

     

    $

    11.0

     

    $

    16.0

     

    $

    17.3

     

    $

    21.7

     

    $

    20.7

     

    * Figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred in historical periods. Figures may not sum due to rounding.

     

    ** MCREM defined as Medicare Equivalent Members, which assumes the level of support received by a Medicare patient is equivalent to that received by three Medicaid or Commercial patients.

     

    *** Platform contribution defined as revenue less external provider costs and cost of care.

     

    Reconciliation to Adjusted EBITDA*

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    $ in thousands

     

    Sep 30,

    2020

     

     

    Dec 31,

    2020

     

     

    Mar 31,

    2021

     

     

    Jun 30,

    2021

     

     

    Sep 30,

    2021

     

     

    Dec 31,

    2021

     

     

    Mar 31,

    2022

     

     

    Jun 30,

    2022

     

     

    Sep 30,

    2022

     

    Net income (loss)

     

    $

    (281

    )

     

    $

    1,218

     

     

    $

    1,302

     

     

    $

    10,057

     

     

    $

    (14,479

    )

     

    $

    (3,553

    )

     

    $

    (16,797

    )

     

    $

    (9,381

    )

     

    $

    (22,053

    )

    GAAP Pro Forma Adjustments

     

     

    (189

    )

     

     

    1,912

     

     

     

    (2,730

    )

     

     

    (6,186

    )

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Pro Forma net income (loss)

     

    $

    (470

    )

     

    $

    3,130

     

     

    $

    (1,429

    )

     

    $

    3,871

     

     

    $

    (14,479

    )

     

    $

    (3,553

    )

     

    $

    (16,797

    )

     

    $

    (9,381

    )

     

    $

    (22,053

    )

    Interest expense

     

     

    1,656

     

     

     

    1,628

     

     

     

    1,400

     

     

     

    1,667

     

     

     

    1,291

     

     

     

    1,905

     

     

     

    1,728

     

     

     

    3,896

     

     

     

    6,076

     

    Depreciation and amortization

     

     

    3,368

     

     

     

    3,418

     

     

     

    2,979

     

     

     

    3,339

     

     

     

    5,176

     

     

     

    6,089

     

     

     

    5,062

     

     

     

    4,903

     

     

     

    4,573

     

    Income tax provision

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    159

     

     

     

    181

     

     

     

    171

     

     

     

    181

     

    Change in fair value of derivative warrant liabilities

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    (1,795

    )

     

     

    (10,227

    )

     

     

    (8,735

    )

     

     

    3,536

     

     

     

    (7,391

    )

     

     

    7,331

     

    Loss (gain) on remeasurement of earnout liabilities

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    (17,420

    )

     

     

    11,625

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Loss on disposal of fixed assets, net

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    50

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Loss (gain) on extinguishment of debt

     

     

    -

     

     

     

    451

     

     

     

    -

     

     

     

    806

     

     

     

    (279

    )

     

     

    7

     

     

     

    -

     

     

     

    6,172

     

     

     

    -

     

    Other expense (income)

     

     

    100

     

     

     

    (997

    )

     

     

    212

     

     

     

    (2,367

    )

     

     

    840

     

     

     

    493

     

     

     

    462

     

     

     

    45

     

     

     

    (87

    )

    EBITDA

     

     

    4,653

     

     

     

    7,630

     

     

     

    3,162

     

     

     

    (11,900

    )

     

     

    (6,053

    )

     

     

    (3,585

    )

     

     

    (5,829

    )

     

     

    (1,585

    )

     

     

    (3,978

    )

    Other adjustments

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Non-recurring expenses

     

     

    2,763

     

     

     

    1,390

     

     

     

    2,795

     

     

     

    8,257

     

     

     

    4,249

     

     

     

    4,653

     

     

     

    6,055

     

     

     

    3,104

     

     

     

    5,940

     

    Acquisition costs

     

     

    789

     

     

     

    893

     

     

     

    1,168

     

     

     

    3,806

     

     

     

    1,871

     

     

     

    2,325

     

     

     

    3,429

     

     

     

    4,074

     

     

     

    2,118

     

    Stock-based compensation expense

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    966

     

     

     

    375

     

     

     

    1,087

     

     

     

    2,788

     

     

     

    3,611

     

    De novo losses**

     

     

    68

     

     

     

    484

     

     

     

    184

     

     

     

    364

     

     

     

    195

     

     

     

    489

     

     

     

    1,119

     

     

     

    993

     

     

     

    1,533

     

    Discontinued operations

     

     

    (35

    )

     

     

    (12

    )

     

     

    (1

    )

     

     

    (0

    )

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Adjusted EBITDA

     

    $

    8,237

     

     

    $

    10,385

     

     

    $

    7,308

     

     

    $

    527

     

     

    $

    1,229

     

     

    $

    4,257

     

     

    $

    5,862

     

     

    $

    9,374

     

     

    $

    9,224

     

    * Pro Forma figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred in historical periods. Figures may not sum due to rounding.

     

    ** Includes operating losses incurred by de novo centers up to 18 months after opening.

     

    Reconciliation to Platform Contribution

     

    $ in thousands

    GAAP Q3 2022

     

    Adjustments

     

    Non-GAAP Q3 2022

     

    Revenue

    $

    157,670

     

    $

    -

     

    $

    157,670

     

    External provider costs

     

    106,900

     

     

    -

     

     

    106,900

     

    Cost of care

     

    30,213

     

     

    (129

    )

     

    30,084

     

    Platform Contribution

     

     

     

     

    $

    20,686

     

     

     

     

     

     

     

     

    External provider costs

    $

    106,900

     

     

     

     

     

     

     

    Medicare and Medicaid risk-based revenue

     

    142,119

     

     

     

     

     

     

     

    Medical Expense Ratio

    75.2

    %

     

     

     

     

     

    $ in thousands

    GAAP Q3 2021

     

    Adjustments

     

    Non-GAAP Q3 2021

     

    Revenue

    $

    104,620

     

    $

    -

     

    $

    104,620

     

    External provider costs

     

    73,329

     

     

    -

     

     

    73,329

     

    Cost of care

     

    21,602

     

     

    (1,287

    )

     

    20,315

     

    Platform Contribution

     

     

     

     

    $

    10,976

     

     

     

     

     

     

     

     

    External provider costs

    $

    73,329

     

     

     

     

     

     

     

    Medicare and Medicaid risk-based revenue

     

    97,312

     

     

     

     

     

     

     

    Medical Expense Ratio

    75.4

    %

     

     

     

     

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005419/en/

    Get the next $CMAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMAX

    DatePrice TargetRatingAnalyst
    2/26/2024$1.50 → $7.50Buy → Hold
    Jefferies
    11/17/2023$5.00 → $1.00Buy → Neutral
    UBS
    11/10/2023$3.00 → $2.00Overweight → Neutral
    Piper Sandler
    3/17/2023$7.00 → $4.00Outperform → Market Perform
    TD Cowen
    9/7/2022$7.50Hold
    Truist
    1/7/2022$14.00Buy
    UBS
    10/20/2021$15.00Buy
    Jefferies
    9/13/2021$14.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $CMAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CareMax Enters Into Agreement to Sell Core Centers' Assets

    ClareMedica Health Partners to become "Stalking Horse" Bidder to Acquire CareMax's Core Centers' Assets CareMax, Inc. (NASDAQ:CMAX, CMAXW)) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced that it has entered into a "stalking horse" purchase agreement with ClareMedica Health Partners ("ClareMedica"), a leader in value-based primary care serving patients in Florida, pursuant to which ClareMedica will acquire CareMax's core centers' assets including a vast majority of CareMax's operating clinics (the "Core Centers' Assets"). The transaction will be implemented pursuant to a previously announced prearranged chapter 11 plan support

    11/25/24 6:30:00 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    CareMax Reaches Agreements to Sell Management Services Organization and Core Centers' Assets

    Revere Medical Enters into Agreement to Acquire CareMax's Management Services Organization Agreement in Principle Reached with "Stalking Horse" for Core Centers' Assets Sale Transactions to be Implemented Through an Expedited Prearranged Chapter 11 Plan Supported by 100% of CareMax's Secured Lenders CareMax Secures $30.5 Million in Debtor in Possession Financing to Support Operations and Continuing Provision of Healthcare Services Throughout Restructuring Process CareMax, Inc. (NASDAQ:CMAX, CMAXW)) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced it has entered into an agreement to sell its management services organization

    11/17/24 6:17:00 PM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    CareMax Reports Second Quarter 2024 Results

    Second Quarter Medicare Advantage Membership of 104,000, up 1% year-over-year Second Quarter Total Revenue of $198.6 million, down 12% year-over-year CareMax, Inc. (NASDAQ:CMAX, CMAXW))) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced financial results for the second quarter ended June 30, 2024. "Although our medical expense ratio continued to run higher than target levels, we were able to manage toward another quarter of sequential improvement in MER in the second quarter, and we continued to make progress against our clinical initiatives," said Carlos de Solo, Chief Executive Officer. Mr. de Solo continued, "Additiona

    8/9/24 5:30:00 PM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    $CMAX
    SEC Filings

    View All

    CareMax Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - CareMax, Inc. (0001813914) (Filer)

    11/25/24 6:35:08 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    CareMax Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

    8-K - CareMax, Inc. (0001813914) (Filer)

    11/18/24 6:55:10 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    SEC Form NT 10-Q filed by CareMax Inc.

    NT 10-Q - CareMax, Inc. (0001813914) (Filer)

    11/13/24 4:56:07 PM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    $CMAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CareMax downgraded by Jefferies with a new price target

    Jefferies downgraded CareMax from Buy to Hold and set a new price target of $7.50 from $1.50 previously

    2/26/24 7:26:58 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    CareMax downgraded by UBS with a new price target

    UBS downgraded CareMax from Buy to Neutral and set a new price target of $1.00 from $5.00 previously

    11/17/23 7:26:57 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    CareMax downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded CareMax from Overweight to Neutral and set a new price target of $2.00 from $3.00 previously

    11/10/23 7:33:59 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    $CMAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Borkowski Edward

    3 - CareMax, Inc. (0001813914) (Issuer)

    10/2/24 5:03:58 PM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    SEC Form 3 filed by new insider Rundell Paul Brent

    3 - CareMax, Inc. (0001813914) (Issuer)

    6/20/24 4:18:15 PM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    Flynn James E converted options into 12,123 shares (SEC Form 4)

    4 - CareMax, Inc. (0001813914) (Issuer)

    11/21/23 6:09:00 PM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    $CMAX
    Leadership Updates

    Live Leadership Updates

    View All

    Steward Health Care Appoints Rubén José King-Shaw Jr to Its Board of Directors

    Steward Health Care, the nation's largest physician-led health care network, today announced the appointment of Rubén José King-Shaw Jr to its Board of Directors. King-Shaw currently serves as Steward's Executive Vice President & Chief Strategy Officer, where he has led a number of critical strategic acquisitions and divestitures including the sale of Steward Health Choice Arizona and the significant merger of Steward's value-based Medicare business with Caremax (NASDAQ:CMAX). King-Shaw also chairs Steward's offshore captive insurance company, TRACO, which is domiciled in Panamá. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220

    7/7/22 5:12:00 PM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    CareMax, Inc. Announces Board Leadership Transition

    CareMax, Inc. ("CareMax") (NASDAQ:CMAX, CMAXW))), a leading technology-enabled provider of value-based care to seniors, today announced the appointment of Mr. Jose R. Rodriguez as Chair of CareMax's board of directors, to succeed Mr. Richard A. Barasch, who has resigned from the Board. Mr. Rodriguez has served as a member of CareMax's board of directors since June 2021 and previously served as CareMax's Lead Independent Director. Mr. Barasch will continue to serve as an advisor to CareMax's board of directors. "We are excited that Jose has agreed to lead CareMax's board of directors as we start our first full year as a public company. The board and I believe Jose's recognized leadership in

    2/7/22 4:30:00 PM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    CareMax, Inc. Appoints Beatriz Assapimonwait to Board of Directors

    CareMax, Inc. ("CareMax") (NASDAQ:CMAX, CMAXW))), a leading technology-enabled provider of value-based care to seniors, today announced that Beatriz Assapimonwait has been appointed as an independent member of the CareMax board of directors. Ms. Assapimonwait brings to CareMax 38 years of Medicare managed care experience, including a decade of experience as a leader in the Medicare markets in South Florida, North Florida, and Puerto Rico. Most recently, Ms. Assapimonwait served as the Regional President for Humana South Florida where she was responsible for developing market strategies and leading market operations. Before that, Ms. Assapimonwait was CEO of Family Physicians of Winter Park

    9/20/21 6:55:00 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    $CMAX
    Financials

    Live finance-specific insights

    View All

    CareMax Reports Fourth Quarter and Full Year 2023 Results

    Met 2023 Guidance for Medicare Advantage Membership and Total Revenue Year-end 2023 Medicare Advantage Membership of 111,500, up 19% year-over-year Full Year 2023 Total Revenue of $751.1 million, up 19% year-over-year Exploring Strategic Options to Maximize Value of Certain Assets and Generate Further Liquidity CareMax, Inc. (NASDAQ:CMAX, CMAXW))) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced financial results for the fourth quarter and full year ended December 31, 2023. "In the fourth quarter, we began taking major steps with the goal of solidifying the long-term viability of our business," said Carlos de Solo, C

    3/18/24 6:55:00 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    CareMax Reports Third Quarter 2023 Results

    Third Quarter Medicare Advantage Membership of 107,000, up 171% year-over-year Third Quarter Total Revenue of $201.8 million, up 28% year-over-year Reaffirming Full Year 2023 Revenue Guidance; Updating Full Year 2023 Medicare Advantage Membership and Adjusted EBITDA Guidance CareMax, Inc. (NASDAQ:CMAX, CMAXW))) ("CareMax" or the "Company"), a leading technology-enabled value-based care delivery system, today announced financial results for the third quarter ended September 30, 2023. "Tomorrow marks one year since the acquisition of our national MSO and nearly two and a half years of rapid growth in our patient and provider base. Over that period, we experienced fluctuations in o

    11/9/23 6:55:00 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    CareMax Schedules Third Quarter 2023 Earnings Conference Call

    CareMax, Inc. ("CareMax") (NASDAQ:CMAX, CMAXW))), a leading value-based care delivery system, announced today that it will release its financial results for the third quarter 2023 before the opening of the financial markets on Thursday, November 9, 2023, and host a conference call at 8:30 am Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (888) 330-2508 for U.S. participants, or (240) 789-2735 for international participants, and referencing conference ID 7874605. A live audio webcast and replay of the event will also be available on the "Events & Presentations" section of CareMax's investor relations website at ir.caremax.com. About CareM

    10/25/23 6:55:00 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    $CMAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CareMax Inc. (Amendment)

    SC 13G/A - CareMax, Inc. (0001813914) (Subject)

    2/14/24 7:36:14 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by CareMax Inc.

    SC 13G - CareMax, Inc. (0001813914) (Subject)

    2/12/24 10:53:22 AM ET
    $CMAX
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13D/A filed by CareMax Inc. (Amendment)

    SC 13D/A - CareMax, Inc. (0001813914) (Subject)

    3/13/23 5:06:40 PM ET
    $CMAX
    Hospital/Nursing Management
    Health Care